658 related articles for article (PubMed ID: 32462717)
1. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
4. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Ali A; Kamjani MH; Kesselman MM
Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
[TBL] [Abstract][Full Text] [Related]
5. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Corominas H; Castellví I; Diaz-Torné C; Matas L; de la Rosa D; Mangues MA; Moya P; Pomar V; Benito N; Moga E; Sosa NH; Casademont J; Domingo P
Medicine (Baltimore); 2021 May; 100(19):e25923. PubMed ID: 34106658
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
7. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
[TBL] [Abstract][Full Text] [Related]
11. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
Cure E; Kucuk A; Cure MC
Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
[TBL] [Abstract][Full Text] [Related]
12. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
13. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
14. [Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm : Perimyocarditis and coagulopathy after administration of tocilizumab].
Bovet M; Wadsack D; Kosely F; Zink W; Zahn R
Anaesthesist; 2021 Feb; 70(2):121-126. PubMed ID: 33064176
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
Knorr JP; Colomy V; Mauriello CM; Ha S
J Med Virol; 2020 Nov; 92(11):2813-2820. PubMed ID: 32628003
[TBL] [Abstract][Full Text] [Related]
16. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review on sarilumab in COVID-19.
Khiali S; Rezagholizadeh A; Entezari-Maleki T
Expert Opin Biol Ther; 2021 May; 21(5):615-626. PubMed ID: 33161757
[No Abstract] [Full Text] [Related]
18. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
19. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Covid-19 cytokine storm by tocilizumab.
Boretti A; Banik B
J Med Virol; 2022 Mar; 94(3):823-828. PubMed ID: 34617604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]